|
PT866720E
(pt)
*
|
1995-11-22 |
2004-06-30 |
Amgen Inc |
Proteina ob para aumentar a massa do tecido mole
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
MEP42108A
(en)
|
1998-10-23 |
2011-02-10 |
Kiren Amgen Inc |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
|
EP1128840A1
(en)
*
|
1998-10-27 |
2001-09-05 |
Eli Lilly And Company |
Prevention of muscle mass loss with leptin receptor ligands
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
MXPA02001417A
(es)
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
AU5943201A
(en)
*
|
2000-05-03 |
2001-11-12 |
Amgen Inc |
Modified peptides as therapeutic agents
|
|
US20020090646A1
(en)
*
|
2000-05-03 |
2002-07-11 |
Amgen Inc. |
Calcitonin-related molecules
|
|
KR20030064275A
(ko)
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
JP2004525621A
(ja)
*
|
2001-01-18 |
2004-08-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
EP1383785B1
(en)
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
JP4606161B2
(ja)
|
2002-05-21 |
2011-01-05 |
アムジエン・インコーポレーテツド |
置換複素環式化合物および使用方法
|
|
WO2004055056A1
(en)
|
2002-12-17 |
2004-07-01 |
Merck Patent Gmbh |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
|
ES2305886T3
(es)
|
2003-12-30 |
2008-11-01 |
Merck Patent Gmbh |
Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
|
|
RU2370276C2
(ru)
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
|
EP1702069A2
(en)
|
2004-01-05 |
2006-09-20 |
EMD Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
RU2437893C2
(ru)
|
2004-12-09 |
2011-12-27 |
Мерк Патент Гмбх |
Варианты il-7 со сниженной иммуногенностью
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
US8716220B2
(en)
|
2005-09-07 |
2014-05-06 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
CA2725143A1
(en)
|
2008-05-21 |
2009-11-26 |
Neurotez, Inc. |
Methods for treating progressive cognitive disorders related to neurofibrillary tangles
|
|
WO2009149379A2
(en)
|
2008-06-05 |
2009-12-10 |
Regents Of The University Of Michigan |
Use of leptin for the treatment of fatty liver diseases and conditions
|
|
SG175233A1
(en)
|
2009-04-22 |
2011-11-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
EP2647706B1
(en)
*
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
RS58010B1
(sr)
|
2012-09-27 |
2019-02-28 |
Childrens Medical Ct Corp |
Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
|
|
PT3074033T
(pt)
|
2013-11-26 |
2019-02-08 |
Childrens Medical Ct Corp |
Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
|
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
|
BR112017011235A2
(pt)
|
2014-12-19 |
2018-02-06 |
Chugai Pharmaceutical Co Ltd |
anticorpos anti-c5 e métodos de uso
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
HUE063647T2
(hu)
|
2016-09-12 |
2024-01-28 |
Amryt Pharmaceuticals Inc |
Eljárások anti-leptin semlegesítõ antitestek detektálására
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|